Related Experiment Video

Updated: Aug 18, 2025

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles
09:57

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles

Published on: June 28, 2021

2.1K

IL-1RAP, a Key Therapeutic Target in Cancer

Jame Frenay1, Pierre-Simon Bellaye1, Alexandra Oudot1

  • 1Plateforme d'Imagerie et Radiothérapie Précliniques, Médecine Nucléaire, Centre Georges-François Leclerc, 21000 Dijon, France.

International Journal of Molecular Sciences
|December 11, 2022
PubMed

Insights

Interleukin-1 receptor accessory protein (IL-1RAP) is a promising new target for cancer therapy. Its overexpression on tumor cells and role in inflammation suggest its potential in developing novel cancer treatments.

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • Cancer remains a leading cause of death globally, necessitating novel therapeutic targets.
  • Current advanced therapies like CAR-T cells and ADCs require specific targets for improved efficacy.
  • Inflammation is increasingly recognized as a key factor in cancer development and progression.

Purpose of the Study:

  • To review the structure, genetics, and role of IL-1RAP in cancer.
  • To explore IL-1RAP as a potential therapeutic target for various cancers.
  • To summarize IL-1RAP-targeting therapies in preclinical and clinical development.

Main Methods:

  • Literature review of IL-1RAP's involvement in inflammation and carcinogenesis.
  • Analysis of IL-1RAP expression in hematological and solid tumors.
  • Survey of current preclinical and clinical studies on IL-1RAP-targeted therapies.

Main Results:

  • IL-1RAP is implicated in IL-1, IL-33, and IL-36 signaling pathways, crucial in inflammation.
  • IL-1RAP is overexpressed on tumor cells across diverse cancer types.
  • Therapeutic strategies targeting IL-1RAP are emerging.

Conclusions:

  • IL-1RAP is a validated target for cancer therapy due to its role in inflammation and tumor cell expression.
  • Targeting IL-1RAP offers a promising avenue for innovative cancer treatments.
  • Further research and clinical development of IL-1RAP-based therapies are warranted.
Keywords:
IL-1R familyIL-1RAPcancerinnovative therapiesmetastasis

More Related Videos

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

484
Author Spotlight: Developing Tools to Tune the Activity of Tyrosine Phosphatases06:56

Author Spotlight: Developing Tools to Tune the Activity of Tyrosine Phosphatases

Published on: September 6, 2024

447

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.8K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
629
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
9.1K